Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment

[Display omitted] •Sorafenib and gadolinium co-loaded liposomes were developed for simultaneous tumor magnetic resonance imaging and therapy.•The solubility of sorafenib in liposome was significantly increased from 0.21μg/mL to 250μg/mL compared to that in water.•Longer imaging time and higher signa...

Full description

Saved in:
Bibliographic Details
Published in:Colloids and surfaces, B, Biointerfaces B, Biointerfaces, 2016-05, Vol.141, p.83-92
Main Authors: Xiao, Yanan, Liu, Yongjun, Yang, Shaomei, Zhang, Bo, Wang, Tianqi, Jiang, Dandan, Zhang, Jing, Yu, Dexin, Zhang, Na
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - chemistry
Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics
Carcinoma, Hepatocellular - diagnostic imaging
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - metabolism
Cell Line, Tumor
Cell Survival - drug effects
Contrast Media - administration & dosage
Contrast Media - chemistry
Drug Delivery Systems
Drug Liberation
Female
Gadolinium - administration & dosage
Gadolinium - chemistry
Hep G2 Cells
Hepatocellular carcinoma
Humans
Liposomes - chemistry
Liver Neoplasms, Experimental - diagnostic imaging
Liver Neoplasms, Experimental - drug therapy
Liver Neoplasms, Experimental - metabolism
Magnetic Resonance Imaging - methods
Mice
Microscopy, Electron, Transmission
MRI-guided
Niacinamide - administration & dosage
Niacinamide - analogs & derivatives
Niacinamide - chemistry
Phenylurea Compounds - administration & dosage
Phenylurea Compounds - chemistry
Sorafenib and gadolinium co-loaded liposomes
Tissue Distribution
Treatment Outcome
Tumor Burden - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Sorafenib and gadolinium co-loaded liposomes were developed for simultaneous tumor magnetic resonance imaging and therapy.•The solubility of sorafenib in liposome was significantly increased from 0.21μg/mL to 250μg/mL compared to that in water.•Longer imaging time and higher signal enhancement was observed at the tumor tissue by SF/Gd-liposome.•SF/Gd-liposomes allowed the MRI-guided in vivo visualization of the delivery and biodistribution of liposome.•SF/Gd-liposome showed significant antitumor effect and better safety properties. To improve the poor water solubility of sorafenib and to monitor its distribution and the early feedback effects on its in vivo treatment efficacy in a precise manner, sorafenib (SF) and gadolinium (Gd) co-loaded liposomes (SF/Gd-liposomes) were prepared. The simultaneous imaging and therapy efficacies of the SF/Gd-liposomes were tested. The solubility of SF in SF/Gd-liposomes was significantly increased from 0.21μg/mL to 250μg/mL. The imaging capability of SF/Gd-liposomes were tested by in-vitro and the in-vivo imaging ability tests and the results confirmed that SF/Gd-liposomes could be served as an effective contrast agent. The design of SF/Gd-liposomes allowed the MRI-guided in vivo visualization of the delivery and biodistribution of liposome. In the in vivo antitumor studies, SF/Gd-liposomes had better antitumor effects in H22 tumor-bearing mice than SF solution (oral or i.v. administration) (P
ISSN:0927-7765
1873-4367
DOI:10.1016/j.colsurfb.2016.01.016